SEC Company Response from Regen BioPharma Inc (RGBP, RGBPP) (CIK 0001589150) (RGBP) — Mar 22, 2017

Regen BioPharma Inc (RGBP, RGBPP) (CIK 0001589150)
Date: March 22, 2017 · CIK: 0001589150 · Accession: 0001607062-17-000107

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-191725

Referenced dates: March 09, 2017

Date

September 30, 2016

Author

David

Form

CORRESP

Company

Regen BioPharma Inc (RGBP, RGBPP) (CIK 0001589150)

Letter

United States Securities and Exchange Commission Attention: Mr. Jim B. Rosenberg Form 10-K for the Fiscal Year Ended September 30, 2016 Filed December 21, 2016 File No. 333-191725

Re: Regen BioPharma, Inc.

Dear Mr. Rosenberg and Ms. Parikh

With regard to the comments of the Staff (the “Staff”) as set forth in its letter dated March 09, 2017 (the “Comment Letter”) relating to the abovementioned Exchange Act filing made by Regen BioPharma, Inc. (The "Company").

The Company is in the process of reviewing the comments and intends to address them fully on or before March 31, 2017.

Thank you for your kind assistance and the courtesies that you have extended to assist us in fulfilling our obligations under the Securities and Exchange Act of 1934. If, at any time, you have any further questions, please let us know.

Sincerely,
David
R. Koos,

Show Raw Text

CORRESP
1
filename1.htm

March
22, 2017

    United States Securities and Exchange Commission

    100 F Street, NE

    Washington, DC 20549

    Attention:
    Mr. Jim B. Rosenberg

    Ms. Sasha Parikh

Re:
Regen BioPharma, Inc.

Form
10-K for the Fiscal Year Ended September 30, 2016

Filed
December 21, 2016

File
No. 333-191725

Dear
Mr. Rosenberg and Ms. Parikh

With
regard to the comments of the Staff (the “Staff”) as set forth in its letter dated March 09, 2017 (the “Comment
Letter”) relating to the abovementioned Exchange Act filing made by Regen BioPharma, Inc. (The "Company").

The
Company is in the process of reviewing the comments and intends to address them fully on or before March 31, 2017.

Thank
you for your kind assistance and the courtesies that you have extended to assist us in fulfilling our obligations under the Securities
and Exchange Act of 1934. If, at any time, you have any further questions, please let us know.

Sincerely,

David
R. Koos,

Chairman
& CEO

SecProbe.io